3[1]Polyzos A,Christou A,Kakolyris S,et al.Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer:a phase Ⅲ randomized trial.J Clin Oncol,2005,23(13):2937-2945.Comment in:J Clin Oncol,2005,23 (13):2882-2883.
4[2]Pfister DG,Johnson DH,Azzoli CG,et al.American society of clinical oncology treatment of unresectable non-small cell lung cancer guideline:Update 2003.J Clin Oncol,2004,2:330-353.
6[4]Sorenson S,Glimelius B,Nygren P; SBU-group.Swedish Council of Technology Assessment in Health Care.A systematic overview of chemotherapy effects in non-small cell lung cancer.Acta Oncol,2001,40(2-3):327-339.
7[5]Gridelli C,Gallo C,Shepherd FA,et al.Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer:a phase Ⅲ trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group.J Clin Oncol,2003,21(16):3025-3034.Comment in:J Clin Oncol,2003,21(16):3009-3010.
8[6]Manegold C,Bergman B,Chemaissani A,et al.Single-agent gemcitabine versus cisplatin-etoposide:early results of a randomised phase Ⅱ study in locally advanced or metastatic non-small-cell lung cancer.Ann Oncol,1997,8(6):525-529; Comment in:513-514.
9[7]Perng RP,Chen YM,Ming-Liu J,et al.Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase Ⅱ randomized study.J Clin Oncol,1997,15(5):2097-2102.
10[8]Fisher MD,D'Orazio A.Phase Ⅱ and Ⅲ trials:comparison of four chemotherapy regimens in advanced non small-cell lung cancer (ECOG 1594).Clin Lung Cancer,2000,2(1):21-22.
